Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : World Heart Corp - WHRT and TSE/WHT -- Ignore unavailable to you. Want to Upgrade?

To: the Chief who wrote (270)	6/4/1999 3:06:00 PM
From: kidl	Respond to of 500

World Heart says underwriters purchase additional shares World Heart Corp WHT Shares issued 14,078,743 Jun 3 close $17.75 Fri 4 Jun 99 News Release Ms. Sandy Armstrong reports Pursuant to the overallotment option arising from the new and secondary share offering completed May 11, 1999, the underwriters have purchased an additional 92,630 common shares, completing distribution under the offering. The common shares were sold at the public offering price of $16.50 (Canadian) or $11.35 (U.S.) per common share, less the underwriting discount, for a total purchase price of $1,436,691 (Canadian). Of the additional common shares, 80,548 were purchased from the company and 12,082 from Dr. Michael C.J. Cowpland, a non-executive director of the company. On May 11, 1999, WorldHeart successfully completed a new issue and secondary offering of 1,955,000 common shares. The issue was priced at $16.50 (Canadian) or $11.35 (U.S.) per common share. Including the option shares, the total number of new shares issued by the company was 1,780,548, for net proceeds to the company, after underwriting discount, of $27,616,300 (Canadian). Issued and outstanding common shares now total 14,078,743. The lead manager of the offering was Merrill Lynch Canada Inc. and the co-managers were ScotiaMcLeod Inc. and CIBC World Markets Inc. WorldHeart intends to use the net proceeds of this offering for continuing research and development activities, product development and commercialization, including costs of clinical trials for its HeartSaverVAD System and related commercialization activities. © Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com